Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression

Perioperative Period Inclusion Criteria: 1. Signed informed consent; 2. Aged ≥ 18 years and ≤ 75 years old, male or female； 3. Patients with a low miR-26 expression in tumor (confirmed by RT-PCR) underwent a curative resection of HCC; 4. The tumor characteristics must meet the following: 1. tumor diameter is between 3 to 8 centimeters,and the number of tumor is less than 3 2. no thrombosis is detected in the main branches of the portal vein, hepatic vein and bile duct by preoperative imaging or by intra-operative findings 3. no extrahepatic and lymph node metastasis Perioperative Period Exclusion Criteria: 1. Concomitant malignant primary tumor(s) in other systems is/are present; 2. The subject receives any previous systemic anti-HCC therapy prior to the resection surgery, such as liver transplantation, intervention, ablation, radiotherapy, chemotherapy, molecular targeted therapy or other anti-HCC therapy; 3. The subject takes other study/investigational drugs during this study; 4. The subject has cerebrovascular accident, renal insufficiency, depression, hyperthyreosis, hypothyroidism or other severe uncontrolled diseases; 5. The subject has a history of study drug or similar drug allergy. Baseline (Post-Surgery 4 to 6 weeks) Inclusion Criteria: 1. Baseline (post-resection) blood routine examination shows that the number of leukocyte\>2.5\*10\^9/L and platelet count\>40\*10\^9/L; 2. Child-Pugh score of class A at baseline. Baseline (Post-Surgery 4 to 6 weeks) Exclusion Criteria: 1. Concomitant malignant primary tumor(s) in other systems is/are present; 2. The subject takes other study/investigational drugs within 4 weeks prior to randomization; 3. The baseline examination indicates that infection, bleeding, bile leakage, or other postoperative complications are present; 4. The baseline examination suggests the presence of tumor metastasis; 5. The subject has cerebrovascular accident, renal insufficiency, depression, hyperthyreosis, hypothyroidism or other severe uncontrolled diseases; 6. The subject has a history of investigational drug or similar drug allergy; 7. The subject is pregnant, lactating, or urine pregnancy test result is positive.